Keywords: UK, NICE, GlaxoSmithKline, Votrient, Renal cell carcinoma

UK’s NICE backs GlaxoSmithKline’s Votrient for the first-line treatment of advanced RCC

Article | 24 December 2010

Print This

The UK’s drug watchdog the National Institute for Health and Clinical Excellence (NICE) has issued the Final Appraisal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in